Tuesday, September 8, 2015
Last of three parts
The results of two recent studies suggest that the dispersion of clinical trials is not nearly as global as commonly believed.
CWWeekly presents this feature as a way to put the spotlight on issues faced by executives in the clinical trials space. Owen Garrick, M.D., is the CEO of Bridge Clinical Research in Oakland, Calif., which is dedicated to increasing the number of minorities and encouraging more Principal Investigators to participate in clinical trials.
The ClinicalTrials.gov registry, which was introduced in 2000, appears to have had a noticeable impact on the number of reported positive and negative effects of heart disease treatments before and after that year, according to a recent PLoS ONE study.
PFS Clinical, a Middleton, Wis.-based provider of turnkey administration solutions that address the key pain points of establishing and running a clinical trial office, has been engaged by the Boston Medical Center (BMC) Clinical Trial Office to provide Medicare Coverage Analysis (CA) of its research trials. PFS Clinical also is helping streamline the transfer of trial information into BMC’s recently deployed clinical trial management system (CTMS) and will provide employee training through its CA workshops.
With declining federal research budgets, those who typically raise money from outside sources to pay for clinical research have an alternative: Charge patients to participate in clinical trials that typically would not get funded.
CWWeekly presents this feature as a way to put the spotlight on issues faced by executives in the clinical trials space. Wendy K.D. Selig is founder and CEO of WSCollaborative, a consulting firm that advises patient advocacy groups and other health-sector clients in defining and implementing strategies for collaborations with industry and government.
It is nearly impossible today to avoid the growing number of commercially available wearable devices capable of gathering health information. These devices—typically placed on a wrist, arm or chest—hold promise for collecting, transmitting and integrating objective experiential data in real time and in aiding the analysis of a much higher volume of data from a significantly larger number of patients. But based on interviews with industry professionals, the conceptual promise of wearable devices in clinical trials remains largely that. Adoption is in its very earliest stages.